- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00372177
The Use of Anti-CD4 Monoclonal Antibody (mAb)-Fragment for the Imaging of Chronic Inflammation in Patients With Active Rheumatoid Arthritis
The Use of Anti-CD4 mAb-Fragment for the Imaging of Chronic Inflammation in Patients With Active Rheumatoid Arthritis (an Open Proof of Concept Study)
Rheumatoid arthritis (RA) is a disease with a large economic impact due to the long lasting disabling nature of the disease. Furthermore, diagnosis of the disease is difficult and only a scheme with different symptoms is used to diagnose rheumatoid arthritis, often only by probability.
Due to the fact that effective disease modifying pharmacological treatment is available and should be started early in established cases of RA, in combination with the adverse effect potential of these substances (e.g. methotrexate), a fast reliable diagnostic tool to diagnose rheumatoid arthritis would be highly appreciated by the medical community and the patients. Furthermore, for invasive treatments (surgery, puncture), an imaging method to display the activity pattern in different joints would be a major advantage.
For the evaluation of the effectiveness of pharmacological therapy in rheumatoid arthritis, up to now, radiological measurements of the destruction process of the joints are used. This method has the disadvantage that it is time consuming insofar as changes in the radiological images must occur. It allows only an evaluation if the joints are destructed (which should be excluded by the new therapy regimen). Again, a quantifiable method for the determination of the effects of new therapeutic approaches would be highly appreciated.
Study Overview
Status
Intervention / Treatment
Detailed Description
The substance will be used as iv injection due to the protein nature of the antibody and, to ensure a fast distribution within the body. The study will be performed as an open clinical trial due to the fact that the applied radiation has to be documented; the use of "placebo" radiation would be unethical.
It is expected, that the new antibody fragment with its radioactive linkage will display an image of the activity distribution of the disease. Due to the fact that only patients with active disease have to be imaged and, to allow for comparison of the activity and the clinical distribution of the disease, this proof of concept study (phase I study) will be performed in patients with active disease. Healthy volunteers could not display an activity pattern of the disease. Furthermore, it seems to be unethical to use volunteers for studies with radioactivity with such a risk/benefit ratio (radiation risks vs. missing chance of display of tissue distribution) in a proof of concept study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Saxony
-
Leipzig, Saxony, Germany, 04103
- Clinic and Policlinic for Nuclear Medicine, Medical faculty, University of Leipzig
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects above 50 years of age
- Suffering from joint pain which is due to active rheumatoid arthritis
- Obvious signs of inflammation in at least one joint (e.g. swelling, erythema, or local elevated temperature)
- Otherwise healthy
- Informed consent
Exclusion Criteria:
- Patients 80 years and older
- Clinically significant disease of the cardiovascular system, respiratory system, hepato-biliary system or central nervous system (CNS)
- Excretory hepatic or renal insufficiency
- Regular intake of any drug, except for hormone replacement therapy in females
- Previous administration of xenogenous proteins
- History of anaphylactic reaction to any drug administered by a parenteral pathway
- Previous participation in a radiopharmaceutical drug trial (unless the effective dose acquired by participation in the current trial will remain below 10 mSv)
- Participation in any clinical drug trial within 3 months prior to enrolment
- Women of child-bearing potential (child-bearing potential to be ruled out by one of the following: at least 2 years past menopause, hysterectomy, bilateral oophorectomy, or bilateral tubal ligation)
- Long term medication with strong antiphlogistic agents/pain killers such as methotrexate, corticoids, or immunosuppressants prior to enrolment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: EP1645
Single-Dose
|
Sterile lyophilized Powder for Preparation of a Solution and sterile labelling Buffer labelling with Tc99m-Pertechnetat Intravenous injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
safety and tolerability of this diagnostic agent
Time Frame: duration of study
|
duration of study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
endpoint for the proof of concept will be the number of patients needed to obtain a series of equal results
Time Frame: duration of study
|
duration of study
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Osama Sabri, Prof. Dr., Clinic and Policlinic for Nuclear Medicine, Medical Faculty, University of Leipzig, Germany
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Biotectid POC EP 1645
- EP 1645
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammation
-
University of EdinburghUmeå UniversityCompletedSystemic Inflammation | Respiratory InflammationSweden
-
University of AarhusAarhus University Hospital; University of CopenhagenCompletedSystemic Inflammation | Airway InflammationDenmark
-
Sykehuset TelemarkRikshospitalet University Hospital; Helse Sor-OstCompletedAirway Inflammation | Peripheral Blood Inflammation Markers | Cement Dust ExposureNorway
-
Assistance Publique - Hôpitaux de ParisCompletedDigestive InflammationFrance
-
Pamukkale UniversityCompletedPeriodontal InflammationTurkey
-
Universidade Federal do ParaCompleted
-
KLE Society's Institute of Dental SciencesCompletedRegenerative InflammationIndia
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
Oral Science International Inc.AdvarraNot yet recruiting
Clinical Trials on Fab-fragment of Anti-human CD4
-
BTG International Inc.GlaxoSmithKlineCompleted
-
Humanigen, Inc.CompletedCystic FibrosisUnited States
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Université NAZI BONIJuvenile Diabetes Research Foundation; International Society for Pediatric... and other collaboratorsRecruitingType 1 DiabetesBurkina Faso
-
University College, LondonMedical Research CouncilNot yet recruitingBronchopulmonary Dysplasia | Chronic Lung Disease of Prematurity | Respiratory Distress Syndrome in Premature Infant
-
Centers for Disease Control and PreventionKenya Medical Research Institute; United States President's Emergency Plan...Completed
-
University of Maryland, BaltimoreRecruiting
-
Nanfang Hospital, Southern Medical UniversityNot yet recruitingAdvanced Solid TumorsChina
-
National Institute of Allergy and Infectious Diseases...Genentech, Inc.Completed
-
National Institute on Aging (NIA)University of Toledo Health Science CampusUnknownHypertension | HemodialysisUnited States